58 related articles for article (PubMed ID: 37923964)
1. Human Epidermal Growth Factor Receptor 2-Low Breast Cancer Brain Metastases: An Opportunity for Targeted Systemic Therapies in a High-Need Patient Population.
Chehade R; Nofech-Mozes S; Plotkin A; Fan KY; Das S; Sahgal A; Moravan V; Jerzak KJ
JCO Precis Oncol; 2024 Mar; 8():e2300487. PubMed ID: 38547418
[TBL] [Abstract][Full Text] [Related]
2. Impact of immunohistochemistry staining conditions on the incidence of human epidermal growth factor receptor 2 (HER2)-low breast cancer.
Kim MC; Kwon SY; Jung HR; Bae YK
Virchows Arch; 2024 May; ():. PubMed ID: 38758231
[TBL] [Abstract][Full Text] [Related]
3. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
5. The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.
Jiang M; Liu J; Li Q; Xu B
Int J Cancer; 2023 Oct; 153(7):1324-1336. PubMed ID: 37314204
[TBL] [Abstract][Full Text] [Related]
6. Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.
Gaudio M; Jacobs F; Benvenuti C; Saltalamacchia G; Gerosa R; De Sanctis R; Santoro A; Zambelli A
Breast Cancer Res Treat; 2024 Feb; 203(3):487-495. PubMed ID: 37923964
[TBL] [Abstract][Full Text] [Related]
7. In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Tyburski H; Karakas C; Finkelman BS; Turner BM; Zhang H; Hicks DG
Lab Invest; 2024 Mar; 104(3):100309. PubMed ID: 38135156
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
9. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
10. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G; Basik M; Niikura N; Tokunaga E; Brucker S; Penault-Llorca F; Hayashi N; Sohn J; Teixeira de Sousa R; Brufsky AM; O'Brien CS; Schmitt F; Higgins G; Varghese D; James GD; Moh A; Livingston A; de Giorgio-Miller V
ESMO Open; 2023 Aug; 8(4):101615. PubMed ID: 37562195
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C; Jacobs F; Agostinetto E; Nader-Marta G; Ceppi M; Bruzzone M; Blondeaux E; Schettini F; Prat A; Viale G; Del Mastro L; Lambertini M; de Azambuja E
ESMO Open; 2023 Aug; 8(4):101592. PubMed ID: 37413762
[TBL] [Abstract][Full Text] [Related]
13. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.
Geukens T; De Schepper M; Richard F; Maetens M; Van Baelen K; Mahdami A; Nguyen HL; Isnaldi E; Leduc S; Pabba A; Zels G; Mertens F; Vander Borght S; Smeets A; Nevelsteen I; Punie K; Neven P; Wildiers H; Van Den Bogaert W; Floris G; Desmedt C
Eur J Cancer; 2023 Jul; 188():152-160. PubMed ID: 37247580
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin E; Presti D; Mariani L; Sposetti C; Leporati R; Menichetti A; Corti C; Benvenuti C; Fucà G; Lobefaro R; Ligorio F; Provenzano L; Vingiani A; Del Vecchio M; Griguolo G; Sirico M; Bernocchi O; Marra A; Zagami P; Agostinetto E; Jacobs F; Di Mauro P; Esposito A; Giorgi CA; Lalli L; Boldrini L; Giacchetti PPB; Schianca AC; Guarneri V; Pedersini R; Losurdo A; Zambelli A; Generali D; Criscitiello C; Curigliano G; Pruneri G; de Braud F; Dieci MV; Vernieri C
NPJ Breast Cancer; 2023 Apr; 9(1):27. PubMed ID: 37069173
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
